# NCT06079112 (NCT06079112)

> 9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer

No report yet. It can be ordered.

- Drugs tested: 9MW2821 plus toripalimab

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06079112
- Phase: PHASE1, PHASE2
- Status: RECRUITING
- Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.
- Conditions: Advanced Urothelial Carcinoma
- Interventions: 9MW2821; Toripalimab
- Enrollment: 100
- Primary outcome: incidence of AE/SAE

## Indexed commentary on NCT06079112 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct06079112